Clinical Trial Update: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Niraparib in combination with anti-PD-L1 antibody maintenance for SLFN11-positive, extensive-stage small cell lung cancer and is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Niraparib (Niraparib)
• anti-PD-L1 antibody

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: SCLC,Extensive Stage, SLFN11-positive | Phase 2 | Status: RECRUITING